-
Sector Analysis
Multiple Myeloma Epidemiology Analysis and Forecast to 2032
Multiple Myeloma Epidemiology Analysis Report Overview In the 8MM, there were 80,305 diagnosed incident cases of multiple myeloma in 2022. The diagnosed incident cases of multiple myeloma are expected to register an AGR of more than 1% during 2022-2032. Multiple myeloma (MM) is a hematologic cancer that forms in a type of white blood cell called plasma cells. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but MM causes cancer cells to accumulate in...
-
Thematic Analysis
Digital Marketing Trends in Colorectal Cancer
Digital Marketing Trends in Colorectal Cancer Report Overview Merck’s Keytruda.com achieved the highest total traffic across colorectal cancer (CRC) patient sites in the US. This was followed by Bristol Myers Squibb’s (BMS’s) Opdivo.com and Roche’s Avastin.com. Overall, the highest proportion of traffic to top branded patient CRC websites originated from direct sources, followed by organic sources. The Digital Marketing Trends in the Colorectal Cancer research report assesses key digital marketing metrics of pharma assets in CRC, including branded websites for patients...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market size in the 8MM was $2.3 billion in 2022. The market will grow at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The Acute Myeloid Leukemia market research report offers an overview of the epidemiology, symptoms, diagnosis, and disease management analysis. The report offers key topics covered including strategic...
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market size for the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) was at $8.4 billion in 2022. The CLL market will register a CAGR of less than 1% from 2022 to 2032. The CLL market research report offers an overview of CLL, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet...
-
Sector Analysis
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Report Overview Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). The subtypes of NHL are defined by the cell of origin, the location involved, and the extensive histopathologic, immunophenotypic, and genetic criteria. B-cell NHLs generally arise in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to distant sites such as the lung or brain in the later...
-
Sector Analysis
Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Ewing Sarcoma Marketed and Pipeline Drugs Report Overview Ewing sarcoma (ES) is an aggressive tumor of adolescents and young adults that constitutes 10% to 15% of all bone sarcomas. The disease is named after James Ewing, who first described it in 1921. These sarcomas originate from unique mesenchymal progenitor cells due to their similar histologic and immunohistochemical characteristics. The most common anatomical sites include the pelvis, axial skeleton, and femur; however, it may occur in almost any bone or soft...
-
Sector Analysis
Next Generation Sequencing Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Next Generation Sequencing (NGS) Tests Market Report Overview The Next Generation Sequencing (NGS) tests market size was valued at $41.9 million in 2022. Next generation sequencing (NGS), or massively parallel sequencing, refers to high-throughput methods for DNA sequencing that are not Sanger-based, based on clonally amplified DNA templates or single DNA molecules rather than electrophoretic separation of chain-termination products produced in individual sequencing reactions. The following are some of the key highlights of the next generation sequencing market are: NGS...
-
Product Insights
Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Multiple Myeloma Clinical Trials Market Overview The Multiple Myeloma (Kahler Disease) clinical trial market research report provides an overview of Multiple Myeloma (Kahler Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Renal Cell Carcinoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Renal Cell Carcinoma Clinical Trials Analysis Report Overview Companies conducted a total of 2335 renal cell carcinoma clinical trials as of May 2023. The Renal Cell Carcinoma clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials as well. Key Regions...
-
Sector Analysis
Melanoma - Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Melanoma–Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional melanoma therapies was $5.5 billion in 2021. The growing aging population, leading to an increased diagnosed incidence of melanoma across age groups will drive market growth during the forecast period. Melanoma–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More About the Melanoma–Cell and Gene Therapies 15-Market Forecast Download a Free Report Sample The...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.